Anzeige
Mehr »
Login
Samstag, 11.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
100 % Anstieg in zwei Tagen: Das technische Signal, das Wall Streets Bären in Panik versetzt!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 918634 | ISIN: FI0009800205 | Ticker-Symbol: ILL
Berlin
10.01.25
19:35 Uhr
3,230 Euro
0,000
0,00 %
1-Jahres-Chart
ILKKA OYJ Chart 1 Jahr
5-Tage-Chart
ILKKA OYJ 5-Tage-Chart
RealtimeGeldBriefZeit
3,2303,24013:02
GlobeNewswire (Europe)
50 Leser
Artikel bewerten:
(0)

Taaleri Oyj: Inside information: Change of Taaleri Plc's CEO - Ilkka Laurila appointed as new CEO

Finanznachrichten News

9.1.2025 08:30:01 EET | Taaleri Oyj | Inside information

TAALERI PLC STOCK EXCHANGE RELEASE 9 JANUARY 2025 AT 8:30 (EET)

Inside information: Change of Taaleri Plc's CEO - Ilkka Laurila appointed as new CEO

Taaleri Plc's CEO Peter Ramsay resigns, and the company's Board of Directors has appointed the company's current CFO Ilkka Laurila as the new CEO. Ramsay will leave his position as CEO and will continue to serve in a special advisory capacity for the Board of Directors for the time being until 8 July 2025 at the latest. Laurila starts as CEO on 9 January 2025.

Laurila (born in 1977) has worked as Taaleri's CFO since February 2024. Prior to that, he has served as CFO of Plugit Finland Oy from 2023 to 2024 and as CFO of Terveystalo from 2015 to 2022. He is a member of the Board of Directors of Nightingale Health Plc and has previously served as a member and Chairperson of the Audit Committee of the Board of Directors of Musti Group.

"We have come to know Ilkka as a results-oriented and well-rounded business developer and strategic thinker, well suited to Taaleri's current stage of development," says Juhani Elomaa, Chairperson of Taaleri's Board of Directors.

"I'm excited about this new challenge. I have become very familiar with Taaleri's organisation over the past year, and I am convinced that we are well placed to accelerate value creation in the company. We are uniquely positioned in growing industries and have a talented workforce," says Ilkka Laurila.

"Taaleri's Board of Directors thanks Peter for his good co-operation as CEO. During his tenure, Taaleri has evolved into a company that focuses on private equity fund management, substantial industrial investments and developing the business of Garantia Insurance Company," Elomaa concludes.

Taaleri will adjust its strategy during the current year and will arrange a Capital Markets Day in autumn 2025.

Helsinki, 9 January 2025
Taaleri Plc
Board of Directors

For further information, please contact:
Juhani Elomaa, Chairperson of the Board of Directors, tel. +358 40 778 9020

Distribution:
Nasdaq Helsinki
Principal media
www.taaleri.com

Taaleri in brief

Taaleri is a Nordic investment and asset manager that focuses on businesses with industrial-scale opportunities within bioindustry and renewable energy. We create value by combining extensive know-how, deep expertise, entrepreneurship and capital through both funds under management and direct investments. We have been a signatory of the UN Principles for Responsible Investment (UNPRI) since 2010, and we joined the Net Zero Asset Managers initiative in 2021. Taaleri's vision is to become a leading investment manager operating internationally in bioindustry and renewable energy.

Taaleri has two business segments: Private Asset Management and Garantia. Private Asset Management consists of bioindustry, renewable energy and real estate businesses. The Garantia segment consists of Garantia Insurance Company.

Taaleri has EUR 2.6 bn of assets under management in its private equity funds and co-investments. The company has approximately 130 employees. Taaleri Plc is listed on Nasdaq Helsinki.

www.taaleri.com

Linda Tierala, Director, Investor Relations and Communications, +358 40 571 7895, linda.tierala@taaleri.com

© 2025 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.